ライフサイエンスコーパス: hemagglutinin

1 ruses spike S2, and the H1N1Ca2009 flu virus hemagglutinin.

2 t assays using a recombinant wild-type 3c2.A hemagglutinin.

3 s and bind the conserved stalk domain of the hemagglutinin.

4 t nonphysiologic, model Ags, such as OVA and hemagglutinin.

5 ng antibodies specific for influenza B virus hemagglutinin.

6 to conserved head and stalk epitopes of the hemagglutinin.

7 bdominant epitopes in the head domain of the hemagglutinin.

8 ent, such as in the case of influenza type A hemagglutinin.

9 taneously inducing high levels of Abs toward hemagglutinin.

10 tralizing humoral immunity against the viral hemagglutinin.

11 he conserved, immunosubdominant stalk of the hemagglutinin.

12 hat is highly focused on antigenic site A of hemagglutinin.

13 s required a combination of mutations in the hemagglutinin.

14 avian H10 hemagglutinin and similar to human hemagglutinin.

15 virus vaccination strategy based on "mosaic" hemagglutinins.

16 influenza A (H7N9) viruses followed by H7N9 Hemagglutinin 1 (HA1) boosting elicited human antibodies

17 essing candidate effectors fused to a double hemagglutinin (2HA) tag were constructed.

18 nza A virus particles in which ectoenzymatic hemagglutinin activation by target cells is a mandatory

19 rminal Asn(221) sequon bound influenza virus hemagglutinin and disrupted influenza A-mediated aggluti

20 ition swine surveillance to characterize the hemagglutinin and full genotypic diversity of IAV at ear

21 y blocking the interaction between the viral hemagglutinin and host cell receptors.

22 st known pH sensing sites in influenza virus hemagglutinin and in variants of murine hepatitis virus,

23 Hemagglutinin and MOG are both presented to T cells, whi

24 ve analyzed the N-glycans of influenza viral hemagglutinin and neuraminidase from several subtypes of

25 pe H3N2 than subtype H1N1 holds only for the hemagglutinin and neuraminidase genes, but not for other

26 d close species-dependent associations among hemagglutinin and neuraminidase subtypes.

27 Hemagglutinin and Neuraminidase undergo antigenic drift

28 In addition, when our Cal/09 LAIV with PR8 hemagglutinin and neuraminidase was used to vaccinate mi

29 hat combining influenza virosomes containing hemagglutinin and neuraminidase with a PAR-2 agonist pep

30 that target the surface viral glycoproteins hemagglutinin and neuraminidase.

31 hows heteromultivalent inhibitory effects on hemagglutinin and neuraminidase.

32 Using hemagglutinin and nucleoprotein Ag-specific B cell tetra

33 H10 hemagglutinin more stable than avian H10 hemagglutinin and similar to human hemagglutinin.

34 omprised of the stem domain from seasonal H3 hemagglutinin and the head domain from avian H7.

35 ly targeted the conserved stalk region of H1 hemagglutinin and was effective against drug-resistant H

36 responding sequences from exotic influenza A hemagglutinins and expressed them as soluble trimeric pr

37 e disease, Lyme disease), trimers (influenza hemagglutinins), and tetramers (influenza neuraminidases

38 larly from inactivated HSV type 2, influenza hemagglutinin, and human papillomavirus E7 protein.

39 The surface glycoproteins, hemagglutinin, and neuraminidase can easily mutate their

40 ically intact prefusion HIV-1 Env, influenza hemagglutinin, and RSV F trimers in the predicted geomet

41 virus, the host generates neutralizing anti-hemagglutinin (anti-HA) antibodies against that specific

42 tibodies against the stem of influenza virus hemagglutinin are promising candidates for the developme

43 We tested this hypothesis using influenza hemagglutinin as a model viral antigen and transgenic, M

44 llular membrane-bound vesicles and with PLD2-hemagglutinin at the plasma membrane.

45 ulation with either ovalbumin or recombinant hemagglutinin B (rHagB) antigen.

46 0050), safety and immunogenicity of chimeric hemagglutinin-based vaccines were tested in healthy, 18-

47 which we named "urumin," is virucidal for H1 hemagglutinin-bearing human influenza A viruses.

48 genic changes, either drift or shift, in the hemagglutinin because NA immunity offers broad protectio

49 ccine development has largely focused on the hemagglutinin, but the other major surface antigen, the

50 We generated mosaic B hemagglutinins by replacing the major antigenic sites of

51 Using antibodies paired to hemagglutinins carrying combinations of escape mutations

52 The consensus hemagglutinin (cHA) stalks for group 1 influenza A virus

53 A vaccination strategy based on chimeric hemagglutinin (cHA), which refocuses the immune response

54 d in mammalian adaptation, antigenicity, and hemagglutinin cleavability.

55 The influenza B virus hemagglutinin contains four major antigenic sites (the 1

56 tive sweeps, coupled with the reemergence of hemagglutinin deletion variants and antigenic drift of n

57 Hemagglutinin deletion variants emerged concomitantly in

58 iable receptor-binding domain (RBD) of viral hemagglutinin displayed on a nanoparticle (np) able to e

59 ins-the proteolytic enzymes that also harbor hemagglutinin domains-significant roles of these protein

60 intramembrane mechanisms by which influenza hemagglutinin drives fusion has been elusive.

61 ple amino acid substitutions within a single hemagglutinin during human infection is rare, thus reduc

62 We show that a pH-stable hemagglutinin enables a human influenza virus to replica

63 complement the receptor-binding function of hemagglutinin, enhancing enzymatic activities of neurami

64 Insertion of a 9-residue hemagglutinin epitope in IS1S2, but not in IS5S6 or in I

65 eting conserved neutralizing influenza virus hemagglutinin epitopes were polyreactive.

66 navirus (RbCoV-HKU14) were identified at the hemagglutinin esterase gene position.

67 ylated sialoglycans via spike protein S with hemagglutinin-esterase (HE) acting as a receptor-destroy

68 s from the two outbreaks have shown that the hemagglutinin-esterase (HE) genes of the viruses fall in

69 umber of encoded amino acid substitutions in hemagglutinin-esterase fusion (HEF) glycoproteins sugges

70 agglutinin esterases and influenza virus C/D hemagglutinin-esterase fusion glycoproteins.

71 of the ligand-binding pockets of coronavirus hemagglutinin esterases and influenza virus C/D hemagglu

72 generate Abs capable of neutralizing variant hemagglutinin-expressing pseudotyped lentiviruses.

73 andidate developmental projects, such as the hemagglutinin-ferritin (HAF) nanoparticle and encephalit

74 mbinant pertussis toxin (PT) and filamentous hemagglutinin (FHA) coadministered with tetanus-diphther

75 Filamentous hemagglutinin (FHA) is a critically important virulence

76 es against pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) were evaluated

77 In our simulations, hemagglutinin first acts within the membrane to increase

78 n coelacanth genomes as well as sequences of hemagglutinin for influenza from New York.

79 Targeting hemagglutinin from influenza A to Clec9A induced Ab resp

80 Six hemagglutinin gene clades were characterized.

81 The first approach was to modify the hemagglutinin gene of a highly pathogenic wild-type (wt)

82 Analysis of the hemagglutinin gene suggested a common ancestry with othe

83 o identify swine-associated sequences in the hemagglutinin gene to differentiate between human-origin

84 RSV G and F proteins and influenza hemagglutinin genes were sequenced.

85 or universal vaccine candidates based on the hemagglutinin globular head and the thoughts about using

86 viruses showed considerable diversity in the hemagglutinin glycoprotein and the egg-adapted vaccine s

87 Differences in hemagglutinin glycosylation site composition and heterog

88 on the influenza vaccine candidate H1ssF, a hemagglutinin (group 1) stabilized stem molecule fused t

89 repertoire against the influenza pandemic H1 hemagglutinin (H1-HA).

90 ke proteins of the influenza A virus (H3N2): hemagglutinin (H3) and neuraminidase (N2).

91 t access to epitopes on the surface antigens hemagglutinin (HA or H) and neuraminidase (NA or N).

92 target the influenza virus surface antigens, hemagglutinin (HA) (including head and stalk regions) an

93 ecreting cells elicited by a candidate COBRA hemagglutinin (HA) (termed P1) were compared with Ab-sec

94 The two conserved epitopes on the influenza hemagglutinin (HA) - the "stem" and the receptor-binding

95 s in replication in avian species, including hemagglutinin (HA) A125T, nucleoprotein (NP) M105V, and

96 rift has been attributed to substitutions in hemagglutinin (HA) acquired during vaccine virus propaga

97 otein sequence and N-linked glycosylation in hemagglutinin (HA) affecting variations in serologic dat

98 The changes in hemagglutinin (HA) affiliated with drift have implicatio

99 epitope in the vestigial esterase domain of hemagglutinin (HA) and blocks HA-mediated membrane fusio

100 engineered glycans onto the influenza virus hemagglutinin (HA) and characterized the molecular featu

101 es were reassortants containing A(H1N1)pdm09 hemagglutinin (HA) and neuraminidase (NA) genes with gen

102 viruses routinely acquire mutations in their hemagglutinin (HA) and neuraminidase (NA) glycoproteins

103 the interaction of the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) with the cell

104 the 2 major viral surface membrane proteins, hemagglutinin (HA) and neuraminidase (NA), mediate prote

105 on is mediated largely by antibodies against hemagglutinin (HA) and neuraminidase (NA), the two major

106 nt interactions of its major spike proteins, hemagglutinin (HA) and neuraminidase (NA), with the cell

107 ruses express two surface glycoproteins, the hemagglutinin (HA) and the neuraminidase (NA).

108 balance between the receptor-binding protein hemagglutinin (HA) and the receptor-cleaving protein neu

109 Fewer serum anti-hemagglutinin (HA) antibody responses with less MMID ind

110 group has demonstrated the effectiveness of hemagglutinin (HA) antigens derived using computationall

111 These H1 COBRA hemagglutinin (HA) antigens induced antibodies with HAI

112 odies (sBnAbs) targeting the influenza virus hemagglutinin (HA) are a promising therapeutic strategy,

113 7/8 agonist 3M-052, in combination with H5N1 hemagglutinin (HA) based antigens.

114 us (IAV) infection, we tested for effects on hemagglutinin (HA) binding and neuraminidase (NA) cleava

115 Cleavage of influenza virus hemagglutinin (HA) by host cell proteases is essential f

116 Cleavage of the viral surface glycoprotein hemagglutinin (HA) by host proteases is a prerequisite f

117 Cleavage of influenza virus hemagglutinin (HA) by host proteases is essential for vi

118 conserved stem region of the influenza virus hemagglutinin (HA) can neutralize many influenza virus s

119 kers and their predicted phenotypic effects, hemagglutinin (HA) clade classifications, an automated t

120 inding and affinity maturation to individual hemagglutinin (HA) domains, HA1 and HA2, across vaccine

121 o poorly immunogenic but conserved influenza hemagglutinin (HA) epitopes.

122 irus vaccines rely on the antigenic match of hemagglutinin (HA) for vaccine strain selection, and mos

123 bined introduction of nucleoprotein (NP) and hemagglutinin (HA) from an H5N1 virus was necessary and

124 ical antigenic conformational epitopes on H5 hemagglutinin (HA) from different clades that were assoc

125 gle amino acid change at position 226 in the hemagglutinin (HA) from glutamine (Q) to leucine (L) has

126 ibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N1 and newly emergent subtypes

127 and intercontinental gene flow based on the hemagglutinin (HA) gene and used representative viruses

128 f adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene from influenza A/PR/8/34 virus.

129 Phylogenetic analysis revealed that the hemagglutinin (HA) gene of H5 isolates belonged to the E

130 ned mutations A125T, A151T, and L217Q in the hemagglutinin (HA) glycoprotein as early as passage 5 an

131 Mutations to the virus hemagglutinin (HA) glycoprotein can modulate virus antig

132 Influenza hemagglutinin (HA) glycoprotein is the primary surface a

133 iruses continuously acquire mutations in the hemagglutinin (HA) glycoprotein that abrogate binding of

134 The activation of influenza virus hemagglutinin (HA) glycoprotein via cleavage by host cel

135 m-targeted Abs against the influenza A virus hemagglutinin (HA) have been well studied, very limited

136 he highly conserved stem region of influenza hemagglutinin (HA) have contributed to considerations of

137 ecognizes a new site of vulnerability on the hemagglutinin (HA) head domain and reacts with most infl

138 ognizes a novel noncontinuous epitope in the hemagglutinin (HA) head domain involving three amino aci

139 Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites can b

140 type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s).

141 Here, we investigated four influenza B virus hemagglutinin (HA) head specific, hemagglutination inhib

142 Advanced, next-generation hemagglutinin (HA) head-based vaccines that elicit prote

143 Antigenic drift of influenza virus hemagglutinin (HA) is enabled by facile evolvability.

144 N139K, located in the head domain of the H2 hemagglutinin (HA) molecule, were identified as importan

145 neutralizing antibodies (bnAbs) to influenza hemagglutinin (HA) naturally develop in humans is critic

146 ed a pattern of epitope substitutions in the hemagglutinin (HA) of each challenge virus that impacted

147 SA) receptors, which preferentially bind the hemagglutinin (HA) of human and avian influenza viruses,

148 accination of the major surface glycoprotein hemagglutinin (HA) of influenza virus with a single N-ac

149 On the hemagglutinin (HA) of the H3N2 IAVs, the amino acid subs

150 Specifically, we tested the compatibility of hemagglutinin (HA) packaging signals from H5N8 and H7N9

151 Key mutations in the virus hemagglutinin (HA) protein or reassortment with other pa

152 cination with an Ad4 expressing an influenza hemagglutinin (HA) protein resulted in anti-HA T-cell re

153 t a single amino acid at position 158 of the hemagglutinin (HA) protein substantially affected the sy

154 The model predicts the region of the virus hemagglutinin (HA) protein targeted by antibodies after

155 ed as a sensitive and selective receptor for hemagglutinin (HA) protein, which is a biomarker for AIV

156 erse epitopes within the "head" of the viral hemagglutinin (HA) protein.

157 luenza viruses target the head domain of the hemagglutinin (HA) protein.

158 oorly understood compared to the response to hemagglutinin (HA) protein.

159 e to glutamine at residue 217 (L217Q) in the hemagglutinin (HA) protein.

160 y, where virions with relatively acid-stable hemagglutinin (HA) proteins are rendered incapable of pH

161 fluenza A virus carries hundreds of trimeric hemagglutinin (HA) proteins on its viral envelope that i

162 , saponin (Matrix-M)-adjuvanted, recombinant hemagglutinin (HA) quadrivalent nanoparticle influenza v

163 utamine (Q226) to leucine (L226), within the hemagglutinin (HA) receptor-binding site (RBS).

164 is lacking compared to what is available on hemagglutinin (HA) responses, despite growing evidence t

165 ns to bind to human-type receptors, increase hemagglutinin (HA) stability, and replicate in human cel

166 Hemagglutinin (HA) stability, or the pH at which HA is a

167 The conserved region of influenza hemagglutinin (HA) stalk (or stem) has gained attention

168 fect the induction of antibodies against the hemagglutinin (HA) stalk domain of influenza viruses.

169 onserved, immuno-subdominant influenza virus hemagglutinin (HA) stalk region is a potential universal

170 Mutations in the hemagglutinin (HA) stalk that increase pH stability have

171 epithelium, we compared the effectiveness of hemagglutinin (HA) stalk-binding bNAbs administered thro

172 Hemagglutinin (HA) stalk-reactive antibodies are the bas

173 nst influenza virus identified the conserved hemagglutinin (HA) stem as a target for development of u

174 The conserved hemagglutinin (HA) stem has been a focus of universal in

175 tibodies (Abs) that bind the influenza virus hemagglutinin (HA) stem may enable universal influenza v

176 res developed antibodies against 3 different hemagglutinin (HA) subtypes, at low prevalence, while ca

177 referred receptor-binding specificity by the hemagglutinin (HA) surface antigen.

178 induced antibody responses target mainly the hemagglutinin (HA) surface glycoprotein, composed of the

179 ting specific antibody responses against the hemagglutinin (HA) surface glycoprotein; however, the di

180 ly conserved stalk region of the influenza A hemagglutinin (HA) surface protein.

181 te reductase degradation domain (DDD) with a hemagglutinin (HA) tag, GFP-DDDHA, which was induced by

182 previously unrecognized epitope of influenza hemagglutinin (HA) that is immunogenic in humans and con

183 us particles displayed an increased ratio of hemagglutinin (HA) to nucleoprotein (NP) and M1 compared

184 tent neutralizing antibodies that target the hemagglutinin (HA) viral surface glycoprotein.

185 om host immune responses, principally on the hemagglutinin (HA) viral surface protein.

186 ic analysis identified T-cell epitopes in H7 hemagglutinin (HA) which potentially enhance regulatory

187 Hemagglutinin (HA), a glycoprotein abundant on the virio

188 The hemagglutinin (HA), a glycoprotein on the surface of inf

189 antibodies to target the viral glycoprotein, hemagglutinin (HA), and critical protective epitopes sur

190 uenza neuraminidase (NA), like those against hemagglutinin (HA), are relatively specific to viruses i

191 Some proteins, like hemagglutinin (HA), NA, and M2, are integral membrane pr

192 head or base of the head domain of influenza hemagglutinin (HA), respectively, and induced destabiliz

193 For influenza virus hemagglutinin (HA), the immunodominance of the variable

194 f a model antibody-antigen complex involving hemagglutinin (HA), the primary immunogenic antigen of t

195 ingle adaptive substitution, G218E, into the hemagglutinin (HA), we generated reassortant A(H7N9)-G21

196 specificity of the receptor-binding protein, hemagglutinin (HA), which recognizes sialic-acid-contain

197 the clonal composition and dynamics of CA09 hemagglutinin (HA)-reactive IgG repertoire over 5 years

198 fection and provide early help to accelerate hemagglutinin (HA)-specific antibody responses.

199 In mice, both T-bet(-) and T-bet(+) hemagglutinin (HA)-specific B cells arose in germinal ce

200 We found that AS03 significantly enhanced H5 hemagglutinin (HA)-specific plasmablast and antibody res

201 oped mouse line expressing a neuron-specific hemagglutinin (HA)-tagged H3.3 protein was used to track

202 PPS) of histidine (His)- and human influenza hemagglutinin (HA)-tags.

203 tterns of the major influenza virus antigen, hemagglutinin (HA).

204 verexpression of the influenza viral protein hemagglutinin (HA).

205 ing site (RBS) of subtype H1 influenza virus hemagglutinin (HA).

206 ise from egg-adaptive mutations on influenza hemagglutinin (HA).

207 ate the utility of PMD using influenza virus hemagglutinin (HA).

208 I IFN receptor 1 (IFNAR1) by utilizing viral hemagglutinin (HA).

209 imized broadly reactive antigens (COBRA) for hemagglutinin (HA).

210 ation of influenza glycoproteins, especially hemagglutinin (HA).

211 hanges that occur predominantly on the viral hemagglutinin (HA).

212 A total of 96 hemagglutinin (HA)/neuraminidase (NA) subtype combinatio

213 IBV are distinguished, based on variation in hemagglutinin (HA): B/Victoria/2/87-like (B/Vic) and B/Y

214 ethod was developed to quantify the absolute hemagglutinin (HA, the main influenza antigen) amount in

215 both fusion (FLAG tags) or both attachment (hemagglutinin [HA] tags) glycoproteins.

216 The conserved stalk of the viral hemagglutinin has been identified as potential target an

217 Hemagglutinins (HAs) from human influenza viruses adapt

218 ntaining wild-type and mutant MN/10 or BJ/92 hemagglutinins (HAs) were constructed and probed for rea

219 ive antibodies against the influenza A virus hemagglutinin have been well studied, very limited infor

220 The results suggest that chimeric hemagglutinins have the potential to be developed as uni

221 The mycobacterial heparin-binding hemagglutinin (HBHA) is a protein Ag with a complex C-te

222 Heparin-binding hemagglutinin (HBHA), a surface protein of Mycobacterium

223 trongly neutralizing mAb (2-12C) against the hemagglutinin head administered prophylactically at 15 m

224 ponses shift focus with age from the mutable hemagglutinin head to other epitopes, consistent with th

225 bnAb elicitation using a single recombinant hemagglutinin immunogen.

226 e noncanonical epitopes of influenza B virus hemagglutinin in animals and humans using novel reagents

227 J-disrupting peptide plus antigen (influenza hemagglutinin) in either a patch-prime or a patch-boost

228 In contrast, the hemagglutinin inhibiting (HI) antibody response evoked b

229 We found that HA head Abs, as measured by hemagglutinin inhibition (HAI) assays, were associated w

230 tion and immunoglobulin genes predicted peak hemagglutinin inhibition (HAI) titers.

231 emarkable serological breadth as measured by hemagglutinin inhibition (HAI).

232 Safety and immunogenicity (hemagglutinin inhibition (HI), microneutralization (MN)

233 near the receptor-binding domain on HA head (hemagglutinin inhibition-positive MAbs) than Flucelvax,

234 o identify residues on the influenza B virus hemagglutinin interacting with the MAbs, we generated es

235 Influenza hemagglutinin is a surface glycoprotein related to virus

236 Two substitutions made seal H10 hemagglutinin more stable than avian H10 hemagglutinin a

237 production of the type IV mannose-sensitive hemagglutinin (MSHA) pilus.

238 Sequential immunization with a stalk-only hemagglutinin nanoparticle elicited group 1 bnAbs, but o

239 Unlike closely related hemagglutinin neuraminidase RBPs from other genera of th

240 for hemagglutination inhibition, full-length hemagglutinin, neuraminidase and hemagglutinin stalk-spe

241 ajor attachment glycoprotein (G) between the hemagglutinin-neuraminidase (HN) and RNA-dependent RNA p

242 n close proximity to paramyxoviral RBPs with hemagglutinin-neuraminidase (HN) functionality, it prese

243 31 distinct swIAV genotypes and 12 distinct hemagglutinin/neuraminidase combinations with largely un

244 detected within the receptor binding site of hemagglutinin of HPAI A/H5N1 viruses, evolved during hum

245 of plasmablast-derived polyclonal Abs to the hemagglutinin of influenza A virus vaccine components, e

246 g to quadrivalent formulations including the hemagglutinins of influenza A subtypes H1N1 and H3N2 and

247 In this study, we used modified hemagglutinins of influenza B virus which display only o

248 Here, we demonstrate that the hemagglutinins of LPAIV strains do not have the required

249 sed Arf6-GFP partially colocalized with PLD1-hemagglutinin on intracellular membrane-bound vesicles a

250 neuraminidase to sialic acids when it abuts hemagglutinin on whole virions.

251 To test this, a novel chimeric hemagglutinin protein (cH7/3) was derived, comprised of

252 C-Ads generate markedly more influenza virus hemagglutinin protein and require substantially less vec

253 n that the membrane-inserted portions of the hemagglutinin protein play a critical role in achieving

254 arrying mutations A125T+A151T+L217Q in their hemagglutinin protein, enabling the virus to overcome va

255 nodominant globular head domain of the viral hemagglutinin protein.

256 substitution at position 222 (D222G) of the hemagglutinin protein.

257 dies that interfere with the function of the hemagglutinin protein.

258 Recombinant mosaic influenza B hemagglutinin proteins and recombinant viruses have been

259 ential vaccination with recombinant mosaic B hemagglutinin proteins conferred cross-protection agains

260 ergence between avian and seasonal influenza hemagglutinin proteins, thus limiting the availability o

261 simulations of fusion between a full-length hemagglutinin proteoliposome and a lipid bilayer to anal

262 nd H7 strains, were measured using influenza hemagglutinin pseudoviruses.

263 Notably, we show that hemagglutinin-reactive MBC expansion reflects imprinting

264 hances broad protection through expansion of hemagglutinin-reactive MBC populations that recognize he

265 ion and changes in the size and character of hemagglutinin-reactive MBC populations.

266 tructure and receptor specificity of the H15 hemagglutinin, revealing distinct features and specifici

267 this approach, 100% sequence coverage of the hemagglutinin sample was obtained.

268 Compared with avian H10 hemagglutinin, seal H10 hemagglutinin showed stronger bi

269 ext flu season using historical glycoprotein hemagglutinin sequence data.

270 nditions for an unprecedented amount of H3N2 hemagglutinin sequences (n = 32 278).

271 By applying GG-MTSL to influenza H3N2 hemagglutinin sequences, we showed the method enables ra

272 escape, and increasing glycosylation of the hemagglutinin shields antigenic sites from antibody bind

273 These novel constructs, termed mosaic hemagglutinins, should provide enhanced protection and s

274 pared with avian H10 hemagglutinin, seal H10 hemagglutinin showed stronger binding to the human-type

275 tion to investigate the relationship between hemagglutinin-specific antibody production and changes i

276 miniscent of its activity on influenza virus hemagglutinin, stabilizes LASV GP to low-pH exposure.

277 influenza viruses, specifically those in the hemagglutinin stalk and neuraminidase, are currently bei

278 Further, we found that hemagglutinin stalk antibodies independently correlated

279 Antibodies against the hemagglutinin stalk confer protection in animal studies(

280 We analyzed antibody responses to H1 hemagglutinin stalk domain (H1/stalk) following trivalen

281 roadly cross-reactive antibodies against the hemagglutinin stalk domain.

282 ws biased usage in human bnAbs targeting the hemagglutinin stalk of group 1 influenza A viruses.

283 We analysed antibody responses to H1 hemagglutinin stalk-domain (H1/stalk) following trivalen

284 echanism of protection mediated by influenza hemagglutinin stalk-reactive antibodies, i.e., inhibitio

285 full-length hemagglutinin, neuraminidase and hemagglutinin stalk-specific antibodies.

286 ing antibody responses against the conserved hemagglutinin stem epitope.

287 All hemagglutinin subtypes of IAVs can infect swine; however

288 influenza A virus, revealing changes in the hemagglutinin surface protein that increase stability an

289 ssessment.IMPORTANCE The pH stability of the hemagglutinin surface protein varies between different i

290 dults correlates with antibody titers to the hemagglutinin surface protein.

291 editing was used to generate mice in which a hemagglutinin tag (HA) was attached to the C-terminus of

292 idopsis (Arabidopsis thaliana) with a triple hemagglutinin tag for rapid purification via a single af

293 y, using the small nine amino acid influenza hemagglutinin tag.

294 e these limitations, we used influenza virus hemagglutinins to engineer a genetically encoded cell-su

295 Further divergence of hemagglutinin variants with poor cross-reactivity could

296 e demonstrate that exposure to the influenza hemagglutinin via natural infection enhances broad prote

297 e antigens cytomegalovirus pp65 or influenza hemagglutinin were able to present the antigens to autol

298 sa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in

299 nant influenza B viruses expressing mosaic B hemagglutinins, which could serve as the basis for a uni

300 cing the major antigenic sites of the type B hemagglutinin with corresponding sequences from exotic i